A Study to Evaluate the Safety and Effectiveness of Restylane-Defyne for Punctual Occlusion
Not Applicable
Completed
- Conditions
- Mild to Moderate Dry Eye Disease
- Interventions
- Device: Restylane Defyne
- Registration Number
- NCT03709641
- Lead Sponsor
- John C Meyer, MD
- Brief Summary
A study which participants with mild to moderate dry eye disease will have a punctum of one eye injected with Restyalne Defyne and the other eye injected with saline solution. Participants will be evaluated over four visits.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Twenty-one (21) to 80 years of age
- Baseline Ocular Surface Disease Index score of at least 13 with no more than 3 responses of "not applicable" for each eye individually
- In the study eye, a baseline Schirmer test with anesthetic of ≤ 10 mm/5 minute
- Literate, able to speak English and able to complete the questionnaire independently
- Willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol.
Exclusion Criteria
- Use of ophthalmic cyclosporine or lifitegrast within 30 days prior to Day 0.
- History of surgical punctal occlusion (e.g., cautery), canalicular infection or canalicular surgery.
- Corneal transplant in either eye
- Ocular surgery (such as cataract surgery or LASIK) in either eye within six months of the Baseline Visit.
- A systemic condition or disease not stabilized or judged by the investigator to be incompatible with participation in the study (e.g. current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease).
- The history or presence of any ocular disorder or condition in either eye that, in the opinion of the investigator, would interfere with the interpretation of the study results (e.g., significant corneal or conjunctival scarring, pterygium or nodular pinguecula; current ocular infection (except mild blepharitis), conjunctivitis or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; history of ocular herpetic infection; evidence of keratoconus; lid or lacrimal cancer.
- Active severe systemic allergy, seasonal allergies, rhinitis or sinusitis requiring treatment (i.e. antihistamines, decongestants, oral or aerosol steroids).
- Use of steroids, including administration by systemic, inhaled or topical ocular routes (dermatologic steroids not applied to the eyelids are allowed).
- Participation in a clinical trial during the past 30 days
- Women who are pregnant, planning a pregnancy, or nursing at study entry
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Restylane Defyne receiver Restylane Defyne Participants will receive Restyane Defyne injected into punctum of one eye.
- Primary Outcome Measures
Name Time Method Evaluating change in Schirmer score from baseline 42 days after screening visit Maximum length of tears absorbed on test strips recorded.
- Secondary Outcome Measures
Name Time Method Evaluating Tear break-up time (TBUT) from baseline. 42 days after screening visit Performed by Keratograph 5M per manufacturer's directions.
Evaluating change in corneal staining score from baseline. 42 days after screening visit 1.0mg sodium fluorescein strips on lower eye lids for one minute. 5 corneal regions graded using cobalt filter to maximized view of fluorescence.
Evaluating change in Ocular Surface Disease index (OSDI) score from baseline 42 days after screening visit Participants answer 12 question questionnaire. Scores from section I,II, and III
Evaluating tear meniscus height from baseline. 42 days after screening visit. Performed by Keratograph 5M per manufacturer's directions.
Trial Locations
- Locations (1)
The Eye Care Institute
🇺🇸Louisville, Kentucky, United States